March 29 (Reuters) - Bioporto A/S:
* BIOPORTO ANNOUNCES FINANCIAL GUIDANCE FOR 2023
* SEES FY23 REVENUE BETWEEN APPROXIMATELY DKK 30 MILLION TO 33 MILLION
* WHILE FDA APPROVAL IS PENDING, COSTS RELATED TO FUTURE CLINICAL STUDIES ARE ASSUMED TO BE LOWER THAN IN 2022
* SEES 2023 ADJUSTED EBITDA LOSS OF APPROXIMATELY DKK 60 MILLION TO DKK 65 MILLION Source text for Eikon: Further company coverage: